Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda entities : Astrazeneca plc save search
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
Published: 2024-02-08 (Crawled : 12:00) - prnewswire.com
AZNCF | News | $140.3 1.13% -4.19% 0
|
Health Technology
|
| O: -8.5%
H: 2.46%
C: 2.46%
IONS | $41.84 1.88% 1.86% 260
|
Health Technology
|
| O: 0.2%
H: 1.37%
C: 0.68%
AZN | News | $70.85 1.03% 1.02% 490K
|
Health Technology
|
| O: -6.81%
H: 3.02%
C: 2.42%
fda granted designation eplontersen
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
Published: 2023-10-13 (Crawled : 13:00) - prnewswire.com
PYXS | $4.5 -0.66% -1.12% 380K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 2.56%
C: 2.56%
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 1.15%
H: 0.0%
C: 0.0%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -1.63%
H: 4.97%
C: 2.76%
MRUS | $40.82 0.92% 0.74% 2
|
Health Technology
|
| O: 0.47%
H: 1.7%
C: -0.38%
AZN | News | $70.85 1.03% 1.02% 490K
|
Health Technology
|
| O: -0.59%
H: 0.62%
C: -0.56%
fda year review cancer pancreatic
Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate
Published: 2023-07-11 (Crawled : 14:00) - biospace.com/
GNPX | $2.31 6.8% 6.77% 0
|
Health Technology
|
| O: 1.25%
H: 3.41%
C: -1.43%
AZN | News | $70.85 1.03% 1.02% 490K
|
Health Technology
|
| O: -0.28%
H: 0.25%
C: -0.23%
fda lung drug candidate cancer cell designation therapy fast track designation
Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer
Published: 2023-06-28 (Crawled : 14:00) - biospace.com/
AZNCF | News | $140.3 1.13% -4.19% 0
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: -2.36%
GNPX | $2.31 6.8% 6.77% 0
|
Health Technology
|
| O: 14.85%
H: 1.18%
C: -7.27%
AZN | News | $70.85 1.03% 1.02% 490K
|
Health Technology
|
| O: -0.29%
H: 0.13%
C: -0.7%
reqorsa fda lung cancer cell treatment designation therapy fast track designation
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
Published: 2022-01-03 (Crawled : 15:00) - biospace.com/
AZNCF | News | $140.3 1.13% -4.19% 0
|
Health Technology
|
| O: 2.49%
H: 1.06%
C: -2.49%
GNPX | $2.31 6.8% 6.77% 0
|
Health Technology
|
| O: 16.79%
H: 0.0%
C: 0.0%
AZN | News | $70.85 1.03% 1.02% 490K
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: 0.07%
keytruda fast track designation treatment fda fast track gene therapy cel fda fast track lung cancer therapy cancer designation
Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca's anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)
Published: 2021-08-02 (Crawled : 12:00) - biospace.com/
AZN | News | $70.85 1.03% 1.02% 490K
|
Health Technology
|
| O: -0.7%
H: 0.86%
C: 0.58%
fda fda approval research approval lupus
Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Published: 2021-06-07 (Crawled : 19:00) - biospace.com/
AZN | News | $70.85 1.03% 1.02% 490K
|
Health Technology
|
| O: -0.32%
H: 0.6%
C: -0.39%
fda fda approval children approval
Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA
Published: 2021-05-10 (Crawled : 16:00) - biospace.com/
BGNE | $138.99 6.15% 5.95% 120
|
Health Technology
|
| O: -0.63%
H: 0.95%
C: -2.15%
AZN | News | $70.85 1.03% 1.02% 490K
|
Health Technology
|
| O: 1.38%
H: 0.27%
C: -0.31%
AMGN | News | $273.54 0.6% 0.65% 8.5K
|
Health Technology
|
| O: 0.7%
H: 1.1%
C: -1.32%
fda license application
US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight to 2026: Insight on FDA Approved 57 Cancer Antibodies Available in the US Market
Published: 2021-04-09 (Crawled : 13:37) - prnewswire.com
AZN | News | $70.85 1.03% 1.02% 490K
|
Health Technology
|
| O: 1.31%
H: 0.02%
C: -0.42%
sales fda clinical trials cancer antibody drug trial fda approval
Gainers vs Losers
| 76% | 24% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
HKIT | $1.33 30.39% 27.14% 39K
|
Technology Services
VRT 4 | $79.17 4.08% 19.36% 6.6M
|
Electronic Technology
PEGY | $0.0566 23.58% 15.65% 11M
|
Manufacturing
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
EAST | $1.0835 16.17% 15.21% 100
|
Commercial Services
BOF | $1.17 6.36% 14.73% 15K
|
LUCY | $0.2545 9.93% 13.94% 66K
|
n/a
PEB 4 | $15.45 2.45% 10.46% 130
|
Finance
MARA | $19.44 10.77% 10.28% 630K
|
Commercial Services
Your saved searches
Save your searches and get alerts when important news are released.